

# UCSF

## UC San Francisco Previously Published Works

### Title

Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure

### Permalink

<https://escholarship.org/uc/item/9q6227f6>

### Journal

Respiratory Research, 23(1)

### ISSN

1465-9921

### Authors

Ghale, Rajani  
Spottiswoode, Natasha  
Anderson, Mark S  
et al.

### Publication Date

2022

### DOI

10.1186/s12931-022-02283-4

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

CORRESPONDENCE

Open Access



# Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure

Rajani Ghale<sup>1,2,3†</sup>, Natasha Spottiswoode<sup>2,3†</sup>, Mark S. Anderson<sup>3,4</sup>, Anthea Mitchell<sup>5</sup>, Grace Wang<sup>5</sup>, Carolyn S. Calfee<sup>1,3†</sup>, Joseph L. DeRisi<sup>5,6†</sup> and Charles R. Langelier<sup>2,3,6\*†</sup>

## Abstract

Auto-antibodies (Abs) to type I interferons (IFNs) are found in up to 25% of patients with severe COVID-19, and are implicated in disease pathogenesis. It has remained unknown, however, whether type I IFN auto-Abs are unique to COVID-19, or are also found in other types of severe respiratory illnesses. To address this, we studied a prospective cohort of 284 adults with acute respiratory failure due to causes other than COVID-19. We measured type I IFN auto-Abs by radio ligand binding assay and screened for respiratory viruses using clinical PCR and metagenomic sequencing. Three patients (1.1%) tested positive for type I IFN auto-Abs, and each had a different underlying clinical presentation. Of the 35 patients found to have viral infections, only one patient tested positive for type I IFN auto-Abs. Together, our data suggest that type I IFN auto-Abs are uncommon in critically ill patients with acute respiratory failure due to causes other than COVID-19.

**Keywords:** COVID-19, Auto-antibodies, Type I interferon, Anti-interferon antibodies, Acute respiratory failure

## Correspondence

Type I interferon (IFN) signaling is an essential component of antiviral innate immunity, and may be impaired in patients with severe COVID-19 [1–4]. Auto-antibodies (Abs) to type I interferons (IFNs) are found in up to 25% of patients with severe COVID-19, but rarely in mild COVID-19 or in healthy controls [1–4], suggesting a decided role in disease pathogenesis. This is further supported by studies demonstrating that patients with autoimmune polyendocrine syndrome type I (APS-1), which leads to type I IFN auto-Ab production in childhood, are predisposed to severe COVID-19 [5].

While several compelling studies have now established a link between type I IFN auto-Abs and COVID-19 severity, it has remained unknown whether their association with severe disease is unique to COVID-19 or common to other forms of severe respiratory illness. To address this question, we studied a prospective cohort of adults without COVID-19 admitted to the intensive care unit (ICU) for acute respiratory failure requiring mechanical ventilation, and measured type I IFN auto-Abs. Clinical and demographic features of the cohort are described in (Table 1). Causes of acute respiratory failure included viral or bacterial pneumonia, non-pulmonary sepsis, stroke or other acute neurologic process, cardiogenic edema, surgical complication, cardiac arrest, and others (Additional file 1: Table S1). Subjects were enrolled between 7/2013 and 3/2020 under University of California San Francisco (UCSF) Institutional Review Board protocol #17-24056.

<sup>†</sup>Rajani Ghale, Natasha Spottiswoode, Carolyn S. Calfee, Joseph L. DeRisi and Charles R. Langelier contributed equally to this work

\*Correspondence: chaz.langelier@ucsf.edu

<sup>2</sup>Division of Infectious Diseases, University of California, San Francisco, CA, USA

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.


**Table 1** Clinical and demographic features of cohort

<b>Age (median, Q1–Q3)</b>	<b>61 (49–70)</b>
Gender (median, %)	
Male	179, 63%
Female	105, 37%
Race (n, %)	
Caucasian	147, 52%
Asian	53, 19%
African American	17, 6%
Pacific Islander	7, 2%
Native American	2, 1%
Other	55, 19%
Unknown	3, 1%
Ethnicity (n, %)	
Non-LatinX	231, 81%
LatinX	53, 19%
Temp Max (median, Q1–Q3)	37.7 (37.2–38.2)
WBC Max (median, Q1–Q3)	12.6 (8.2–17.3)
Pneumonia (n, %)	107, 38%
Viral pneumonia (n, %)	35, 12%
28-day mortality (n, %)	71, 25%
Intubated (n, %)	284, 100%
Vasopressors (n, %)	178, 63%
*Immunocompromised (n, %)	48, 17%

\*Solid organ transplant, hematopoietic stem cell transplant, HIV infection, leukemia, lymphoma

Auto-Abs to IFN- $\alpha$ 2 were measured from plasma collected within 72 h of intubation using a radioligand binding assay (RLBA), according to previously developed methods [2]. A positive signal was defined as greater than 2 standard deviations above the mean of pre-COVID-19 blood bank healthy controls (n=18). Three patients with APS-1 were also included as positive controls. Subjects with pneumonia were identified using a previously described adjudication protocol [6], and screened for viral pathogens by clinical respiratory viral PCR testing, SARS-CoV-2 PCR for those enrolled after 01/2020, and metagenomic next generation RNA sequencing, following established protocols [6].

Of the 284 subjects with acute respiratory failure, only three (1.1%) tested positive for type I IFN auto-Abs by RLBA (Fig. 1). These included a man with fatal rhinovirus pneumonia, a woman with post-operative complications of aneurysm repair and suspected thymoma, and a man with post-operative hemorrhage (Fig. 1). While each had different underlying clinical presentations, all were over the age of 67, which is associated with increased prevalence of type I IFN auto-Abs [3], and one had a probable thymoma, which is also associated with these auto-Abs [7]. With respect to non-COVID-19 viral pneumonia, one of 14 patients with rhinovirus infection had type I IFN auto-Abs



(~7%); notably, this patient was also a bone marrow transplant recipient and had been diagnosed with graft-vs-host disease. For other viruses, including influenza (n = 11), parainfluenza (n = 6), metapneumovirus (n = 2), and seasonal coronavirus (n = 2), no positives were detected.

Interferon signaling is a hallmark feature of viral respiratory infections including those due to influenza virus, SARS-CoV-2, and other pathogenic species [8, 9]. In contrast, our data demonstrate that detection of type I IFN auto-Abs is uncommon in critically ill patients with acute respiratory failure due to non-COVID-19 causes. This suggests that their association with pneumonia severity may have specificity for COVID-19, in line with the observation that auto-Abs to type I IFN are amongst the greatest risk factors for COVID-19 severity [3]. Given the relatively small numbers of distinct respiratory viral species represented in the cohort, we cannot exclude the possibility that type I IFN auto-Abs are associated with other severe viral pneumonias, although our results suggest an overall prevalence much lower than the 11–25% observed for patients with critical COVID-19 [1–4].

Strengths of our study include a large cohort size, detailed clinical phenotyping, and a prospective cohort of patients with acute respiratory failure from diverse causes. While our use of both clinical PCR testing and metagenomic sequencing for respiratory virus detection is also a strength, the relatively small number of confirmed respiratory viral infections is a limitation. Measurement of only a single type I IFN may also be a limitation, although prior work has demonstrated that IFN- $\alpha$ 2 auto-Abs are most strongly associated with COVID-19 severity, and neutralize other type I IFNs, which somewhat alleviates this concern. We also recognize that factors such as timing and signaling magnitude have to be considered when evaluating the effects of interferon induction on target cells. Further studies are needed to assess the prevalence of auto-Abs against proteins other than type I IFNs in patients with critical illness from COVID-19 and other causes. Additional work is also needed to clarify the mechanisms underpinning the apparent specificity for type I IFN auto-antibodies in critical COVID-19 pneumonia.

### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12931-022-02283-4>.

**Additional file 1: Table S1.** Source data for Fig. 1 including patient ID, RLBA Z-score versus pre-COVID-19 blood bank healthy controls, viruses detected, and etiology of respiratory failure for each patient.

### Acknowledgements

We are grateful to the contributions of Jenny Wilson, Thomas Deiss, Farzad Moazed and Michael Matthey to cohort development.

### Author contributions

RG: patient enrollment, sample processing, data interpretation, manuscript writing. NS: data interpretation and manuscript writing and clinical data review and analysis. AM, GW: anti-interferon antibody measurements. MA: development of control cohort, data interpretation, manuscript writing. CC: development of cohort, study design, supervision, data interpretation, manuscript writing. JD: study design, supervision, data interpretation, manuscript writing. CL: study design, supervision, data interpretation, sample processing, manuscript writing. All authors read and approved the final manuscript.

### Funding

This work was supported by the National Heart, Lung and Blood Institute [R35 HL140026 (CSC), K23HL138461-01A1 (CL)], and the Chan Zuckerberg Biohub (AOP, AB, AK, CRL, JLD).

### Availability of data and materials

Source data are provided with this paper in Additional file 1: Table S1.

### Declarations

#### Ethics approval and consent to participate

Ethics approval and consent to participate was obtained from the UCSF Institutional Review Board protocol according to protocol number 17-24056, as described in detail previously [9].

#### Consent for publication

Consent to publish was obtained from the UCSF Institutional Review Board protocol according to protocol number 17-24056.

#### Competing interests

The authors declare no competing interests.

#### Author details

<sup>1</sup>Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco, CA, USA. <sup>2</sup>Division of Infectious Diseases, University of California, San Francisco, CA, USA. <sup>3</sup>Department of Medicine, University of California, San Francisco, CA, USA. <sup>4</sup>Diabetes Center, University of California, San Francisco, CA, USA. <sup>5</sup>Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA. <sup>6</sup>Chan Zuckerberg Biohub, San Francisco, CA, USA.

Received: 13 May 2022 Accepted: 7 December 2022

Published online: 16 December 2022

### References

- Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science*. 2020;370:eabd4585.
- van der Wijst MGP, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. *Sci Transl Med*. 2021;13:eabh2624.
- Bastard P, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. *Sci Immunol*. 2021;6:eabl4340.
- Goncalves D, et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. *Clin Transl Immunol*. 2021;10.
- Bastard P, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. *J Exp Med*. 2021;218:e20210554.

6. Langelier C, et al. Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults. *Proc Natl Acad Sci USA*. 2018. <https://doi.org/10.1073/pnas.1809700115>.
7. Meager A, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. *Clin Exp Immunol*. 2003;132:128–36.
8. Wu W, Metcalf JP. The role of type I IFNs in influenza: antiviral superheroes or immunopathogenic villains? *J Innate Immun*. 2020;12:437–47.
9. Sarma A, et al. Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. *Nat Commun*. 2021;12:5152.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

